Crescent Biopharma, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging -4.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.78 | $-0.74 | +5.1% | Beat | |
| Q1 FY26 | $-0.85 | $-0.70 | +17.6% | Beat | |
| Q4 FY25 | $-2.22 | $-4.01 | -80.6% | Miss | |
| Q3 FY25 | $-1.01 | $-1.27 | -25.7% | Miss | |
| Q2 FY25 | $-2.69 | $-4.93 | -83.3% | Miss | |
| Q1 FY25 | not reported | $-0.04 | not reported | not reported | |
| Q4 FY24 | $-0.16 | $-0.11 | +31.3% | Beat | |
| Q3 FY24 | not reported | $-0.15 | not reported | not reported | |
| Q1 FY24 | $-0.16 | $-0.17 | -6.3% | Miss | |
| Q4 FY23 | $-0.15 | $-0.14 | +6.7% | Beat | |
| Q3 FY23 | $-0.14 | $-0.14 | +0.0% | Beat | |
| Q2 FY23 | $-0.18 | $-0.13 | +27.8% | Beat |
Back to CBIO overview · CBIO holders · CBIO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.